Ipsen selects Pierrick Lefranc as new EVP Technical Operations

Credit: HJBC / Shutterstock.com

Pierrick Lefranc will become Ipsen’s new Executive Vice President (EVP) of Technical Operations on 1 April.

He will take over from Aidan Murphy, the French biopharma company’s current EVP Technical Operations, who is set to retire in March.

During his 30 years in the pharmaceutical industry, Pierrick has led manufacturing operations and large-scale industrial projects. Since July 2019 he has served as Ipsen’s Senior Vice President, a role focused on manufacturing, engineering and enterprise activities.

After joining the biopharma company in 2013, Pierrick began to lead its Signes site in France in 2016.

David Loew, Ipsen’s CEO, said: “I am pleased to welcome Pierrick to the Executive Leadership Team, bringing with him decades of leadership and strategic transformation expertise gained both within Ipsen and across major pharmaceutical companies.

“I would also like to extend my sincere appreciation for Aidan’s commitment to Ipsen and wish him much success and happiness in his next chapter. Throughout his leadership roles, Aidan has built a first-class manufacturing team across the globe while driving transformation and excellence within Technical Operations, which has been recognised by several Shingo awards.”

Pierrick said he is looking forward to being an integral member of Ipsen’s ongoing transformation.

This executive shift follows the company’s €1 billion acquisition of ImCheck Therapeutics last October. The deal adds a potential first-in-class anti-BTN3A monoclonal antibody to Ipsen’s oncology pipeline. The biologic modulates both innate and adaptive immunity, and clinical data suggests that combining Ven-Aza (venetoclax and azacitidine) and ICT01, could provide a novel immunotherapy for AML.

The firm made a smaller oncology licensing deal in July 2024 with Day One Biopharmaceuticals for rights to the kinase inhibitor tovorafenib in a paediatric indication.